Longevity is losing credibility.
Hype Beast
Consumer wellness and deep biotech are both being sold as “longevity” — diluting the word, causing confusion, and drawing pushback.
Bull. Now boasting ~1.3K companies and ~$21B in investments, the longevity sector’s annual deal value jumped from <$600M to >$4B in a decade. Aging research accelerated at 9% CAGR over the last five years, with experts developing shared language and frameworks for markets, regulators, and clinicians.
Borg. The dawn of AI has fueled hype alongside funding, with startups claiming they’ll soon solve all disease. Meanwhile, DTC platforms are multiplying, capitalizing on lack of institutional trust to win consumers with dubious anti-aging claims.
Snake. With health literacy lacking and subject matter experts short on pop-sci comms skills, some companies are banking on slick marketing and vibes. As wellness, luxury, and longevity blur, the latter risks being written off as snake oil.
Bro. Despite helping mainstream the topic, Huberman told Men’s Health the longevity space is “a circus.” Warning it’s become as “pathetic” as “looksmaxxing,” he notes public perception is spiraling. Insisting optimization culture took his words out of context, he emphasized being healthy means being flexible — with true wellness built on “little things that cost nothing.”
Bear. Speaking to The Times, Arianna Huffington and Dr. Eric Topol agreed AI health hype is getting out of hand, calling the notion it will eradicate illness unrealistic. The Information reported scientists see AI leaders as “false prophets,” highlighting how breakthroughs like DNA sequencing in 2000 produced similar hype, yet chronic disease has become more common.
Long Game
Clarifying verbiage, BCG and Super Human Network say “geroscience” is the mechanism, while longevity and healthspan are outcomes.
With consumer longevity startups overhyping still-early science, experts like Dr. Jamie Justice, Joe Betts-LaCroix, and professor Andrea Maier are calling for stronger commitment to evidence culture before the field’s credibility is permanently undermined.
Punchline: As opportunists prey on regulatory ambiguity and health anxiety, credentialed leaders are getting more vocal to prevent the whole plot from imploding.
